Eli Lilly and Company successfully recovered the domain mounjaroinovador.site from Bruno Dutra after the respondent used the site to sell unauthorized weight-loss products to Brazilian consumers. The WIPO panel ordered the transfer of the domain, citing clear trademark infringement and bad faith usage.
Case Snapshot
| Case Number | D2026-3517 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | Bruno Dutra |
| Disputed Domain | mounjaroinovador.site |
| Threat Tactic | Corporate Impersonation |
| Decision Date | 2026-09-30 |
| Panelist | Gonçalo M. C. Da Cunha Ferreira |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3517 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationBusiness and Consumer Risks of Trademark Impersonation
The use of the domain ‘mounjaroinovador.site’ created a substantial threat to both the integrity of the MOUNJARO brand and the safety of the consuming public. By deploying a Portuguese-language website targeting Brazilian consumers, the respondent actively sought to capitalize on the reputation of Eli Lilly’s pharmaceutical product. The use of the ‘Mounjaro de Pobre’ branding—translated as ‘Poor Man’s Mounjaro’—leveraged the established trademark to drive traffic to an unauthorized platform. This tactic not only diverted potential customers but also fostered a false sense of institutional legitimacy, misleading users into believing the site offered a genuine, safe alternative to the complainant’s medication.
Beyond the immediate impact of traffic diversion, this case highlights the severe reputational and legal risks associated with unauthorized associations in the healthcare sector. The respondent utilized testimonials and unverified health claims to sell a purported natural weight-loss recipe, a practice which directly endangered consumer trust. By linking these unregulated health products to a recognized pharmaceutical brand, the respondent created a high-risk environment where users might rely on potentially misleading information under the guise of an authentic commercial entity. Such activities pose a direct challenge to brand owners, as they must mitigate the fallout from public confusion and the potential for real-world harm resulting from the consumption of unverified substances marketed under their trademark.
Panel Reasoning: Navigating Trademark Impersonation and Consumer Harm
The panel determined that the disputed domain name, ‘mounjaroinovador.site,’ was confusingly similar to the Complainant’s MOUNJARO trademark. By incorporating the trademark in its entirety alongside the descriptive Portuguese term ‘inovador’ (meaning ‘innovative’), the Respondent failed to avoid a finding of infringement. The panel further noted that the generic Top-Level Domain (gTLD) ‘.site’ was insufficient to distinguish the domain from the Complainant’s legitimate brand presence, reinforcing the conclusion that the domain was designed to capture traffic through brand association.
Regarding the lack of rights or legitimate interests, the respondent failed to provide a formal defense, which expedited the panel’s review. The evidence established that the Respondent was not commonly known by the disputed name and had no relationship with Eli Lilly and Company. The panel emphasized that the burden rests on the Respondent to demonstrate a legitimate interest under the non-exhaustive list of circumstances defined in the UDRP, and the absence of any rebuttal left the Complainant’s prima facie case unchallenged.
The finding of bad faith was underscored by the Respondent’s use of the site to target Brazilian consumers with unauthorized medical products. By branding the site as ‘Mounjaro de Pobre’—effectively ‘Poor Man’s Mounjaro’—the Respondent explicitly traded on the reputation of the MOUNJARO mark to sell unverified weight-loss recipes. The panel highlighted that the registration of such a domain by an unaffiliated party constitutes opportunistic bad faith, particularly when the site leverages misleading health claims that may induce consumer reliance based on the misplaced trust in the Complainant’s global brand identity. This use was deemed inherently harmful, as it deliberately creates a likelihood of confusion for commercial gain.
Strategic Drivers of Success in the Mounjaro Case
The success of Eli Lilly and Company in securing the transfer of the mounjaroinovador.site domain rested on a meticulous documentation of brand provenance versus the respondent’s unauthorized commercial activity. By anchoring the case in the global registration history of the MOUNJARO trademark and the verified timeline of the product’s 2022 market launch, the complainant provided the panel with an undeniable factual baseline. This evidentiary clarity allowed the panel to easily categorize the respondent’s use of the site as opportunistic. The inclusion of clear, dated screen captures—which demonstrated the specific Portuguese-language marketing of a competing ‘natural’ weight-loss recipe—effectively mapped the complainant’s intellectual property to the respondent’s deceptive commercial gain.
Furthermore, the respondent’s failure to engage in the UDRP process proved fatal to any potential defense, allowing the panel to draw adverse inferences regarding a lack of legitimate interests. The complainant’s strategy of explicitly framing the respondent’s activity as a public health risk—highlighting how ‘Mounjaro de Pobre’ branding misled Brazilian consumers into associating unverified weight-loss claims with the established pharmaceutical brand—was pivotal. This proactive positioning moved the discussion beyond mere trademark infringement to underscore the potential for actual consumer harm. This analytical angle helped secure a persuasive ruling that prioritized brand integrity and market protection in an increasingly localized digital environment.
Practical Recommendations
- Prioritize evidence of consumer confusion by documenting localized terms like ‘Mounjaro de Pobre’ to demonstrate how respondents adapt global trademarks for specific regional markets.
- Proactively monitor secondary market and new gTLD registrations containing core trademarks, as failure to respond by the infringing party does not alleviate the need to provide comprehensive evidence of malicious intent.
- Submit historical screenshots showing the evolution of the site’s content (e.g., from passive holding to active sales) to provide the panel with a clear narrative of the respondent’s opportunistic bad faith.
- In cases involving health-related products, emphasize the potential for consumer harm and public safety risks, as panels are more likely to view unauthorized commercialization of medicinal brands as an aggravated form of bad faith.
- Ensure UDRP filings include detailed jurisdictional evidence of trademark usage, specifically linking global pharmaceutical approvals to the local region targeted by the infringing domain.
Frequently Asked Questions (FAQ)
Why did the panel consider ‘mounjaroinovador.site’ confusingly similar to the MOUNJARO trademark?
The panel ruled that the disputed domain incorporated the MOUNJARO trademark in its entirety. The addition of the descriptive Portuguese term ‘inovador’ (meaning ‘innovative’) did not mitigate the confusion, and the generic top-level domain ‘.site’ was disregarded in the assessment.
How did the respondent attempt to use the MOUNJARO brand for commercial gain?
The respondent used the domain to host a Portuguese-language website targeting Brazilian consumers. By branding the site as ‘Mounjaro de Pobre’ (‘Poor Man’s Mounjaro’) and offering a weight-loss recipe, the respondent intentionally traded on Eli Lilly’s reputation to sell competing products, creating a false association with the complainant’s brand.
What evidence proved the respondent acted in bad faith?
Bad faith was established because the respondent had no formal relationship with Eli Lilly and used a domain incorporating a well-known, coined trademark to sell unauthorized, unverified medical products. The panel noted that this opportunistic behavior misleads consumers who may rely on the complainant’s trusted reputation when considering health claims.
Did the respondent provide any arguments to defend their use of the domain?
No. The respondent failed to file a formal response to the UDRP complaint or provide any evidence of rights or legitimate interests in the domain. Consequently, the panel relied on the complainant’s evidence, which demonstrated that the registrant was not commonly known by the domain and was using it for deceptive commercial purposes.
Facing corporate impersonation through a domain?
Unauthorized sites using your brand to sell competing products can severely dilute your trademark and pose health risks to your customers. Learn how to identify and dismantle high-risk impersonation domains effectively.
This case note is for informational purposes only and is not legal advice.
